Modeling New Therapeutic Approaches for Malignant Melanoma
模拟恶性黑色素瘤的新治疗方法
基本信息
- 批准号:8633274
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-10-01 至 2017-09-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAffectAgeAgonistAmericanAntibodiesAntitumor ResponseApoptosisBRAF geneCell AgingCell CycleCell DeathCellsCessation of lifeChemical ExposureChemotherapy-Oncologic ProcedureClinical TrialsCombined Modality TherapyDNA DamageDataDisease regressionEffectivenessEpidemicGene MutationGrowthHumanImmuneImmunologic SurveillanceImmunotherapyImplantInduction of ApoptosisLeukocytesLinkMDM2 geneMEKsMalignant NeoplasmsMelanoma CellMetastatic MelanomaMitosisModelingMusMutateMutationMyeloid CellsNeoplasm MetastasisOperative Surgical ProceduresPathway interactionsPatientsPharmaceutical PreparationsPhase II Clinical TrialsPhenotypePlacebosPopulationProductionProgression-Free SurvivalsPropertyProteinsRecruitment ActivityRelapseResistanceResistance developmentSevere Adverse EventStabilizing AgentsStagingSun ExposureT cell responseTNFRSF10A geneTNFRSF10B geneTNFSF10 geneTestingTherapeuticTimeToxic effectTumor Cell InvasionUbiquitinationUnresectableVeteransaurora kinaseaurora-A kinasebasechemotherapydeath receptor-4designexperiencehuman TNFRSF10A proteinimprovedinhibitor/antagonistkinase inhibitormacrophagemelanomamutantneoplastic cellnovel therapeutic interventionolder menpre-clinicalpreclinical studypublic health relevancereceptorresearch studyresponsesenescencesuccesstherapeutic effectivenesstumortumor growthtumor microenvironment
项目摘要
DESCRIPTION (provided by applicant):
Metastatic melanoma is one of the fastest growing tumor types in the US, especially in Veterans, and also is one of the most challenging malignancies to treat. While there has been some recent success for melanoma tumors that carry the BRAFV600 mutation, the response is transient and treatment is complicated by development of resistance as well as secondary tumors. Both BRAFWT and BRAFV600 melanoma tumors are eligible for treatment with CTLA-4 or PD1 antibody to boost the T cell response to tumor, only 20-30 percent of the tumors respond with the 2-4 month increase in overall survival. Our preclinical experiments have focused on stopping tumor growth by blocking cell cycle with the Aurora kinase A (AURKA) inhibitor, MLN8237. Most human melanoma tumors implanted into immune deficient mice respond strongly to therapy with MLN8237, but the drug largely induces senescence and slows tumor growth, but does not cause regression. We now have strong preliminary data showing that combining the AURKA inhibitor with inhibitors of MDM2 or activators of death receptors 4 or 5 (DR4, DR5) pushes the tumor cells rendered senescent by MLN8237 into apoptosis and causes tumor regression. We now want to carryout advanced pre-clinical studies using these combinations of therapy to treat human melanoma tumor implants into mice to test the hypothesis that combining AURKA inhibitor therapy with agents that stabilize p53 by inhibition its ubiquitination by MDM2 or agents that activate DRs will provide improved therapy for late BRAFWT melanoma or melanomas that develop resistance to BRAF inhibitors. There are 3 specific aims: Aim IA: To characterize the effectiveness of combined therapy with the MDM antagonist, Nutlin-3a, and the AURKA inhibitor, MLN8237, for treatment of BRAFWT/p53WT, NRasmutant/p53WT, NRasWT/p53WT melanoma. Aim IB. To examine the effect of the Nutlin-3a and MLN8237 combination treatment on the growth of BRAFV600 /p53WT melanoma tumor implants from patients that have developed resistance to BRAF inhibitors. Aim IIA. To characterize the effects of combined treatment with MDM2 antagonist Nutlin-3a and AURKA inhibitor MLN8237 on tumor microenvironment an on melanoma metastasis. Aim IIB. To evaluate the potential for boosting the antitumor response of myeloid cells to enhance melano-ma tumor cell death in association with MLN8237 and Nutlin-3a. We will express constitutively active IKK¿ in myeloid cells to push them into an antitumor phenotype. Melanoma tumors growing in mice with WT or constitutively active IKK¿ in myeloid cells will be treated with MLN8237 and Nutlin-3a and growth of tumor and metastatic properties of tumor will be evaluated. Aim IIIA. To characterize the effectiveness of combining treatment with agonist for the death receptors DR4 and DR5 with MLN8237 for treatment of BRAFWT, NRAS WT or NRAS mutant melanoma tumors that are either p53WT or p53mutant. Aim IIIB. To evaluate the effectiveness of combined DR5, DR4 agonists with MLN8237 for BRAF inhibitor resistant BRAFV600 melanoma.
描述(由申请人提供):
转移性黑色素瘤是美国增长最快的肿瘤类型之一,尤其是在退伍军人中,也是最具挑战性的恶性肿瘤之一。虽然最近在携带 BRAFV600 突变的黑色素瘤肿瘤方面取得了一些成功,但这种反应是短暂的,并且由于耐药性和继发性肿瘤的发展,治疗变得复杂。 BRAFWT 和 BRAFV600 黑色素瘤肿瘤都适合用 CTLA-4 或 PD1 抗体治疗,以增强 T 细胞对肿瘤的反应,只有 20-30% 的肿瘤有反应,总生存期增加 2-4 个月。我们的临床前实验重点是通过极光激酶 A (AURKA) 抑制剂 MLN8237 阻断细胞周期来阻止肿瘤生长。大多数植入免疫缺陷小鼠体内的人类黑色素瘤肿瘤对 MLN8237 治疗反应强烈,但该药物很大程度上会诱导衰老并减缓肿瘤生长,但不会引起消退。我们现在拥有强有力的初步数据表明,将 AURKA 抑制剂与 MDM2 抑制剂或死亡受体 4 或 5(DR4、DR5)激活剂相结合,可推动 MLN8237 导致衰老的肿瘤细胞凋亡并导致肿瘤消退。我们现在希望使用这些组合疗法来治疗植入小鼠体内的人类黑色素瘤肿瘤,以进行高级临床前研究,以测试以下假设:将 AURKA 抑制剂疗法与通过抑制 MDM2 泛素化来稳定 p53 的药物或激活 DR 的药物相结合,将为晚期 BRAFWT 黑色素瘤或对 BRAF 抑制剂产生耐药性的黑色素瘤提供改进的治疗。有 3 个具体目标: 目标 IA:表征 MDM 拮抗剂 Nutlin-3a 和 AURKA 抑制剂 MLN8237 联合疗法治疗 BRAFWT/p53WT、NRasmutant/p53WT、NRasWT/p53WT 黑色素瘤的有效性。目标IB。旨在检查 Nutlin-3a 和 MLN8237 联合治疗对来自对 BRAF 抑制剂产生耐药性的患者的 BRAFV600 /p53WT 黑色素瘤肿瘤植入物生长的影响。目标IIA。旨在表征 MDM2 拮抗剂 Nutlin-3a 和 AURKA 抑制剂 MLN8237 联合治疗对肿瘤微环境和黑色素瘤转移的影响。目标IIB。评估与 MLN8237 和 Nutlin-3a 相关的增强骨髓细胞抗肿瘤反应以增强黑色素瘤细胞死亡的潜力。我们将在骨髓细胞中表达组成型活性 IKK,以将它们推向抗肿瘤表型。将用 MLN8237 和 Nutlin-3a 治疗在骨髓细胞中具有 WT 或组成型活性 IKK 的小鼠中生长的黑色素瘤肿瘤,并评估肿瘤的生长和肿瘤的转移特性。目标IIIA。旨在表征死亡受体 DR4 和 DR5 激动剂与 MLN8237 联合治疗 p53WT 或 p53 突变的 BRAFWT、NRAS WT 或 NRAS 突变黑色素瘤的有效性。目标 IIIB。评估 DR5、DR4 激动剂与 MLN8237 联合治疗 BRAF 抑制剂耐药性 BRAFV600 黑色素瘤的有效性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ann Richmond其他文献
Ann Richmond的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ann Richmond', 18)}}的其他基金
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)
BLR
- 批准号:
10618231 - 财政年份:2020
- 资助金额:
-- - 项目类别:
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)
BLR
- 批准号:
10454101 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
优化乳腺癌免疫检查点抑制剂治疗的反应:PI3K 通路抑制剂的作用
- 批准号:
10305634 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
优化乳腺癌免疫检查点抑制剂治疗的反应:PI3K 通路抑制剂的作用
- 批准号:
9916443 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
优化乳腺癌免疫检查点抑制剂治疗的反应:PI3K 通路抑制剂的作用
- 批准号:
10531596 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
免疫治疗与靶向治疗相结合以提高黑色素瘤的生存率
- 批准号:
10609814 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
免疫治疗与靶向治疗相结合以提高黑色素瘤的生存率
- 批准号:
10369756 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Modeling New Therapeutic Approaches for Malignant Melanoma
模拟恶性黑色素瘤的新治疗方法
- 批准号:
8817140 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
免疫治疗与靶向治疗相结合以提高黑色素瘤的生存率
- 批准号:
10265337 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Modeling New Therapeutic Approaches for Malignant Melanoma
模拟恶性黑色素瘤的新治疗方法
- 批准号:
8966669 - 财政年份:2013
- 资助金额:
-- - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
-- - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
-- - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual